Primary Assessment Method: Median Progression-Free Survival, Arm A
Number of patients enrolled	94
Number of patients evaluable for toxicity	87 (43 in Arm A, 44 in Arm B)
Number of patients evaluated for efficacy	84
Evaluation method	RECIST 1.1
Response assessment, CR	0 (0%)
Response assessment, PR	5 (11.6%)
Response assessment, SD	14 (32.6%)
Response assessment, PD	13 (30.2)
Median duration assessments, PFS	2.6 months (95% CI, 1.8-3.5)
Median duration assessments, OS	6.7 months (95% CI, 4.9-9.5)
Median duration of treatment	2.0 cycles